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ABSTRACT
CD200, a protein belonging to the immunoglobulin superfamily, has been 
associated with a poor prognosis in lymphoproliferative disorders and in acute 
leukemia. We studied the expression of CD200 in a series of 244 patients with 
diagnosis of acute myeloid leukemia (AML), to evaluate its impact on outcome and 
its possible association with other known prognostic factors.
CD200 was found in 136/244 (56%) patients, in 41 of whom (30%) with 
high intensity of expression (MFI ≥ 11). CD200 was more frequent in secondary 
compared to de novo leukemia (p = 0.0006), in CD34 positive cases (p = 0.00001), 
in Bcl2 overexpressing cases (p = 0.01), in those wild-type Flt3 (p = 0.004) and 
with favorable or unfavorable compared to intermediate karyotype (p = 0.0003). 
CD200+ patients have a two-fold lower probability to attain complete remission, 
both in univariate (p = 0.006) and multivariate (p = 0.04) analysis. The negative 
impact of CD200 was found also in overall survival (p = 0.02) and was correlated 
with the intensity of expression of the molecule (p = 0.024). CD200 has an additive 
negative impact on survival in patients with unfavorable cytogenetic (p = 0.046) and 
in secondary leukemia (p = 0.05), and is associate with a worsening of outcome in 
patients with favorable biological markers, such as mutated NPM (p = 0.02), wild-type 
Flt3 (p = 0.034), negativity of CD34 (p = 0.03) and of CD56 (p = 0.03).
In conclusion, CD200 is emerging as both a prognostic factor and a potential 
target of novel therapeutic approaches for AML, aiming to reverse the “do not eat me” 
signal of CD200 or to manipulate the suppressive immune microenvironment induced 
by CD200 binding to its receptor.
INTRODUCTION
Despite relatively high rates of complete remission 
(CR) with induction and consolidation chemotherapy, 
relapse occurs in the majority of adult patients with 
acute myeloid leukemia (AML), accounting for the poor 
likelihood of long-term survival. [1, 2]
Besides clinical and laboratory features at 
diagnosis, such as age, performance status, tumor burden, 
antecedent hematological disorder or prior exposure to 
chemotherapy and extramedullary disease [3–6], various 
cytogenetic or molecular abnormalities are currently used 
for risk stratification [7, 8]. The genetic features of AML, 
identifies in the last decades along with the understanding 
of leukemia biology, are pivotal to move towards a patient-
tailored therapy and follow-up. [9–13] However, to date 
only little improvement in survival rate has been observed, 
especially in high-risk patients, despite a wider use of stem 
cell transplantation (SCT), that is still considered the best 
consolidation therapy in poor-risk AML for the graft-
versus-leukemia action of allogeneic T- cells [14–19].
Given these premises, it is clear that mechanisms 
by which tumor cells can hamper immune recognition 
and survive in a permissive microenvironment should 
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be taken into account. CD200 is a type-1 membrane 
glycoprotein containing two immunoglobulin 
domains, normally expressed in a broad range of 
cells. [20] Its binding with CD200R is able to induce 
an immunosuppressive signal and, in animal models, 
favors the tumor growth [21–25]. In hematological 
malignancies CD200 expression was first reported in 
chronic lymphocytic leukemia, where it has a role in 
differential diagnosis with mantle cell lymphoma [26]. 
Lack of CD200 expression in plasma cells has been 
associated with more aggressive multiple myeloma. 
[27] More recently CD200 aberrant expression has been 
proposed as an adverse prognostic factor in AML. [28]
Since the relative paucity of data and the somehow 
conflicting results, aim of our study is to assess the pattern 
of CD200 expression in a series of adult patients with 
AML, its association with other known prognostic factors 
and the possible impact on clinical outcomes.
PATIENTS AND METHODS
Two hundred forty-four patients with diagnosis of 
non-promyelocytic AML admitted at the Divisions of 
Hematology of Udine and Siena between January 2008 
and June 2014 were included in the study. Clinical and 
biological characteristics at diagnosis are summarized in 
Table 1. Diagnosis was performed on bone marrow smears 
according to FAB classification. [29] Cytogenetic risk was 
classified according to MRC criteria [30]. Flt3 and NPM 
mutations were evaluated as previously described. [31, 32] 
Combined molecular and cytogenetic risk was assigned 
according to Döhner. [9]
Blast cells immunophenotype was evaluated by 
multiparametric flow cytometry (Facs Diva II, BD). 
CD200 aberrant presence on blast cells was tested using 
PE anti-human CD200- antibody (BD Pharmingen, 
Brussels, Belgium) and expressed as the percentage of 
positive cells (with 20% as cut-off value) and as the 
mean fluorescence intensity (MFI) obtained by the ratio 
of fluorescence intensity of the test and of its isotypic 
control. Cases with a MFI = 1 were considered negative, 
patients with a MFI < 11 as “low expressing” and case 
with MFI ≥ 11 were considered as “high expressing”.
Patients were treated according to Ethic Board 
approved Institutional protocols with induction 
chemotherapy and at least two consolidation courses 
after complete remission (CR). High-risk cases (defined 
as at least one of the following: secondary AML, poor 
response to induction chemotherapy, unfavorable 
cytogenetic or combined genetic risk, or patients 
with early relapse) underwent allogeneic stem cell 
transplantation (SCT) from related or unrelated donor. 
Poor performance status or elderly patients, deemed 
not suitable for intensive chemotherapy, received 
cytoreduction with hydroxyurea, low-dose cytarabine 
or oral 6-mercaptopurine.
Definitions and statistical analysis
Complete remission (CR) was defined as the complete 
peripheral hematological recovery and the absence of bone 
marrow disease (at morphological, immunophenotypic or 
molecular evaluation). Overall survival (OS) was calculated 
from diagnosis to death (irrespective from the cause). 
Leukemia free survival (LFS) was defined as the time 
between CR and relapse. Patients lost to follow up were 
censored at the time last seen alive.
Categorical variable were compared with Fisher 
exact test or Yates corrected chi square test, as required. 
Comparisons between continuous variables were evaluated 
by T student test or by Kruskall Wallis test. Factors 
affecting CR were assessed by univariate and multivariate 
logistic regression, and expressed as HR (95%CI). OS 
curves were constructed by Kaplan Meier method and 
differences among groups calculated by log-rank test. 
The Cox proportional hazard regression model was 
used to examine the potential prognostic factors for OS: 
all variables with p values ≤ 0.10 in univariate analysis 
were included in the multivariable model and a backward 
stepwise procedure was applied to identify significant 
factors. All p-values are 2-sided at a significance level 
of 0.05. Statistics was performed by NCSS 10 Statistical 
Software (2015) (“NCSS, LLC. Kaysville, Utah, USA, 
http://ncss.com/software/ncss.”).
RESULTS
Aberrant expression of CD200 was found in 
136/244 patients (56%) with a mean MFI of 11 (range 
2–100). High intensity of expression (mean MFI = 23.5 
± 10) was detected in 41/136 (30%) positive patients. As 
shown in Table 2, CD200 was more frequently expressed 
in secondary leukemia (52/71, 73%), compared to de 
novo (84/172, 49%; p = 0.0006), while no association 
was found with age, WBC count at diagnosis and FAB 
subtype. However CD200 was more frequently expressed 
in CD34 positive blast cells (p < 0.00001) and in patients 
with high levels of Bcl2 (p = 0.01), while there was an 
inverse correlation with CD56 expression (39/87, 45% 
in CD56+ vs 95/154, 62% in CD56 negative patients; 
p = 0.015).
High frequency of CD200 expression was detectable 
in patients without Flt3-ITD mutation (105/170, 62%) 
compared to patients with Flt3-ITD mutation (17/46, 
37%, p = 0.004) and in patients with wild type NPM 
(99/145, 68%) vs those with mutated NPM (19/65, 29%, 
p = 0.0013).
Considering karyotype, a lower frequency of 
CD200 positivity was found in intermediate cytogenetic 
group (65/139, 47%), compared to favorable (13/14, 
93%) and unfavorable risk group (44/67, 66%; p = 
0.0003), and in the favorable or intermediate groups 
of the combined cytogenetic/molecular classification 
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(74/150, 49%) compared to the unfavorable (48/69, 69%; 
p = 0.02).
CD200 and response to induction therapy
One hundred forty-nine out of 244 (61%), 
obtained CR, 10/244 (4%) died during induction and 
85/244 (35%) were resistant to induction therapy. 
Relapse occurred in 54/149 (36%) patients at a median 
of 30 months.
Factors affecting CR probability are listed in Table 3. 
In univariate analysis, age higher than 55 years (p < 
0.00001), secondary disease (p < 0.00001), CD34 positivity 
(p = 0.0001) and unfavorable cytogenetics (p = 0.01) or 
unfavorable molecular/cytogenetic status (p = 0.00001) 
were associated with reduced probability to achieve CR. CR 
was obtained in 73/130 (56%) in CD200+ and in 76/100 
CD200- (76%) evaluable patients (p = 0.006). Patients 
with aberrant CD200 expression have almost two fold less 
probability to obtain CR (OR = 0.45, 95% CI: 0.26–0.80).
Table 1: Clinical/biological characteristics at diagnosis
n. 244
Età Median (range) yrs
Età ≥ 55
59 (18–84)
147
Sex: M/F 173/71
WBCx109/L: mean ± 2SD
WBC ≥ 30 × 109/L
13.9 ± 42.5
98 (40%)
Type of leukemia : De novo
        Secondary
173 (71%)
71 (29%)
FAB (de novo): M0
        M1
        M2
        M4
        M5
        M6
10 (6%)
  32 (18%)
  28 (16%)
  35 (20%)
  65 (38%)
  3 (2%)
Combined cytogenetic/molecular risk:
Favorable
Int-1
Int-2
Unfavorable
NA
43 (18%)
61 (25%)
35 (14%)
70 (29%)
35 (14%)
Flt3-ITD: mutated
     wild type
     NA
46 (19%)
170 (70%)
28 (11%)
NPM: mutated
   wild type
   NA
65 (27%)
145 (59%)
34 (14%)
Cytogenetic risk:
Favorable
Intermediate
Unfavorable
NA
14 (6%)
136 (56%)
70 (29%)
24 (10%)
CD34: positive
   negative
130 (53%)
114 /47%)
CD56: positive
   Negative
   NA
87 (36%)
154 (63%)
3 (1%)
Bcl2-MFI: ≥ 17
      < 17
      NA
124 (51%)
113 (46%)
7 (3%)
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The negative impact of CD200 on remission 
probability was maintained in multivariate analysis 
(p = 0.04), along with more conventional factors such 
as age (p = 0.002), type of leukemia (p = 0.002), CD34 
positivity (p = 0.008) and unfavorable cytogenetic risk 
(p = 0.0025) (Table 3).
Overall survival
At the time of analysis 101/244 patients (41%) 
were alive without evidence of disease, with a 3-year 
survival probability of 37% (95%CI: 29–43). Three-
year OS was significantly reduced in patients aged ≥ 
55 years compared to younger patients (21% vs 60%, 
p < 0.0001), in case of secondary AML (20% vs 43% 
in de novo leukemia, p = 0.0004), and in CD34 positive 
cases (23%, vs 53% in CD34- patients, p < 0.0001). As 
expected, unfavorable karyotype was associated with 
poorer survival (3-year OS 22%, compared to 40% in 
normal/intermediate and 60% in favorable cytogenetic, 
p = 0.0003). No impact on OS was also observed for 
Flt3-ITD, both in the whole population and in the 
normal/intermediate cytogenetic subgroup. Conversely 
the presence of a NPM mutation conferred a survival 
advantage irrespective to karyotype with a 3-year OS 
50% in mutated vs 33% in WT (p = 0.01). Considering 
the combined cytogenetic/molecular risk, OS in the 
unfavorable group (30% at 3 years) was significantly 
lower compared with the other risk groups (58% in 
favorable, 43% in intermediate-1, 34% intermediate-2; 
p = 0.0001). With regard of CD200, OS was negatively 
affected by both aberrant molecule expression (3-year 
OS 31% vs 45%; p = 0.02, Figure 1a), and by intensity 
of expression (17% in patients with high MFI compared 
to 36% in those with low intensity of expression; p = 
0.024) (Figure 1b).
In multivariate analysis (Table 4), advanced 
age (HR = 0.46, 95%CI 0.30–0.69), unfavorable 
cytogenetic (HR = 0.33, 95%CI 0.13–0.79), CD34 
positivity (HR 0.44, 95%CI 0.29–0.67) and CD200 
Table 2: CD200 and clinical/biological characteristics at diagnosis
CD200+ P
Age: ≥ 55 yrs
   < 55 yrs
84/147 (57%)
53/97 (55%)
0.79
Type of leukemia : De novo
         Secondary
84/172 (49%)
52/71 (73%)
0.0006
Cytotype: M0
     M1-M2
     M4-M5
     M6
7/16 (43%)
35/65 (54%)
56/111 (50%)
1/3 (33%)
0.8
WBC: ≥ 30 × 109/L
   < 30 × 109/L
48/99 (48%)
87/145 (60%)
0.08
Cytogenetic: Favorable
       Intermediate
       Unfavorable
13/14 (93%)
65/139 (47%)
44/67 (66%)
0.0003
Flt3-ITD: Positive
     Negative
17/46 (37%)
105/170 (62%)
0.004
NPM: Wild type
   Mutate
99/145 (68%)
19/65 (29%)
0.0013
Cytogenetic/molecular risk: Favorable
             Intermediate-1
             Intermediate-2
             Unfavorable
23/44 (52%)
31/70 (44%)
20/36 (55%)
48/69 (69%)
0.02
CD34: Positive
   Negative
99/129 (77%)
36/113 (32%)
< 0.00001
CD56: Positive
   Negative
39/87 (45%)
95/154 (62%)
0.015
Bcl2 MFI: ≥ 17
      < 17
65/101 (64%)
66/136 (48%)
0.01
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MFI ≥ 11 (HR 0.57, 95%CI 0.32–0.97) retained their 
negative prognostic role.
Association of CD200 with other prognostic 
factors and outcome
We then evaluated the impact of the expression 
of CD200 in different biologically/molecularly defined 
prognostic groups.
Patients with unfavorable karyotype expressing CD200 
have a survival rate significantly lower than CD200 negative 
patients (3-year OS 11% vs 39%, p = 0.046) (Figure 2a). We 
found a trend for a lower OS according to CD200 intensity 
of expression: 3-year survival rate was 18% in CD200-
low compared to 0% in CD200-high expressing patients 
(Figure 2b). A worse survival was observed also in patients 
with favorable cytogenetic and high CD200 expression 
(33%) compared to those CD200-low (79%). The lack of 
statistical significance is probably due to the small size of 
the two groups. Instead, CD200 positivity did not influence 
survival probability in the intermediate cytogenetic risk.
Considering Flt3, co-expression of CD200 did not 
worsen survival probability in Flt3-ITD+ patients, but 
negatively affected survival in ITD-negative patients; 
3-year OS was 42% in CD200-, 36% in CD200-low 
and 0% in CD200-high patients (p = 0.034, Figure 3a). 
Table 3: Uni and multivariate analysis of potential factors for CR
Univariate Multivariate
OR (95%CI) p-value OR (95%CI) P-value
Age ≥ 55 yrs 0.23 (0.12–0.43) < 0.00001 0.40(0.19–0.87) 0.0019
WBC ≥ 30 × 109 0.6 (0.36–1-11) 0.1
Secondary leukemia 0.19 (0.10–0.35) < 0.00001 0.31(0.15–0.65) 0.0019
Unfavorable 
Cytogenetic
0.08 (0.005–0.61) 0.01
Unfavorable 
Cytogenetic/
molecular
0.07 (0.025–0.24) 0.00001 0.12(0.03–0.47) 0.0025
NPM unmutated 0.26 (0.12–0.55) 0.0004
CD34 positive 0.27 (0.15–0.48) 0.0001 0.36(0.17–0.77) 0.008
CD56 positive 0.74 (0.42–1.30) 0.27
CD200 positive 0.52(0.29–0.91) 0.02
CD200 MFI ≥ 11 0.41 (0.19–0.92) 0.03 0,49(0.20–0.95) 0.040
Bcl-2 MFI ≥ 17 0.78 (0.45–1.35) 0.38
Figure 1: Overall survival of the entire population according to CD200 expression, p = 0.02, a. and by CD200 intensity 
of expression, p = 0.024, b. CD200 negative: MFI = 1; CD200 low: MFI < 11; CD200 high: MFI ≥ 11.
a b
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In NPM mutated patients CD200 was less frequent than 
in NPM WT ones, but, when present, CD200+/NPM 
mutated cases had a lower OS rate compared to their 
CD200- counterpart (3-year OS 63% vs 25%, p = 0.02, 
Figure 3b). In NPM-WT patients 3-year OS was 29% in 
CD200+ and 37% in CD200- cases (p = 0.1).
No difference in survival probability was found 
according to CD200 status in CD56+ patients. Conversely in 
CD56- AML, CD200 expression was associated with a lower 
survival probability: 3-year OS was 57% in CD200-, 35% 
in CD200-low and 0% in CD200-high patients (p = 0.03; 
Figure 4a). As for CD56, no impact on survival was observed 
for CD200 in CD34+ patients, while in the CD34-negative 
group CD200 high was associated with worse 3-year OS 
probability: 0% compared with 59% in CD200 low and 57% 
in CD200 negative patients (p = 0.03, Figure 4b).
Last, CD200 had a negative impact on OS in both 
de novo and in secondary AML. At 3-year, in de novo 
cohort OS was 49% in CD200- and 35% in CD200+ 
patients (p = 0.04; Figure 5a). In secondary AML 3-year 
Table 4: multivariate analysis of factors for OS
HR (95%CI) P
Age ≥ 55 yrs 0.46 (0.30–0.69) 0.0002
Secondary leukemia 0.92 (0.61–1.39) 0.78
Unfavorable cytogenetic risk 0.33(0.13–0.79) 0.01
CD34 positivity 0.44 (0.29–6.67) 0.0002
CD200 MFI ≥ 11 0.59 (0.32–0.97) 0.04
Figure 3: Overall survival by CD200 intensity of expression in patients FLT3-ITD negative p = 0.034, a. and in NPM 
mutated group, p = 0.02, b.
a b
Figure 2: Overall survival in patients with unfavorable cytogenetics: difference in CD200 negative and in CD200 
positive patients, p = 0.046, a. and according to CD200 MFI, p = 0.06, b.
a b
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OS was 38% in CD200- and 16% in CD200+ (p = 0.05; 
Figure 5b).
DISCUSSION
Along with factors promoting drug resistance or 
favoring neoplastic cells’ escape from programmed death, the 
mechanisms by which AML can evade immunosurveillance 
have recently gained new attention. Many ways are employed 
by leukemic cells to escape recognition and destruction by 
immune effector cells, such as down-regulation of HLA 
molecules, secretion of inhibitory cytokines, recruitment 
of tolerogenic cells, modification of costimulatory and 
co-inhibitory signals. In the present paper we focused on 
the potential impact of CD200 expression on outcome of a 
series of 244 adult patients with non-promyelocytic AML. 
We found an aberrant expression of CD200 in 56% of cases, 
with a high intensity of expression in 30%. Differently from 
what has been reported by Tonks at al [28] we did not find 
differences in CD200 expression among FAB subtypes, but 
in our series 77% of CD34-positive expressed also CD200. 
Many authors reported an association between CD200 and 
stem cell properties in solid tumors [33–35], suggesting 
that cancer stem cells use CD200 system to prevent the 
attack of the immune system. In our cases we did not find 
association with other marker of leukemic stemness. As in 
the work by Tonks et al. [28], aberrant CD200 expression 
was detected in the vast majority (93%) of AML cases with 
favorable cytogenetic, but we found high rate of CD200 
positivity also in patients with unfavorable katyotype 
(P = 0.0003), NPM1 wild type (P = 0.001), Flt3-ITD negative 
(P = 0.004), and with unfavorable cytogenetic/molecular 
status, as recently defined by Döhner [9] (P = 0.02). 
Moreover CD200 was more frequently expressed secondary 
than in de novo leukemia (73% vs 49%).
CD200 positivity was associated with lower rates 
of complete remission and survival, as confirmed in 
multivariable analysis. Tonks and coworkers [28] found a 
negative impact on survival in the whole population and the 
subgroup with core binding factor AML. Analyzing survival 
in the different cytogenetic risk groups, we found a negative 
impact of CD200 expression in patients with unfavorable 
karyotype, while in cases with CBF alterations the lack of 
significance is probably due to the limited number of patients. 
Figure 4: Overall survival according to CD200 MFI in CD56 negative patients, p = 0.04, a. and in CD34 negative 
patients, p = 0.03, b.
a b
Figure 5: Overall survival by CD200 expression in de novo, p = 0.04 a. and secondary leukemia, p = 0.05 b.
a b
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Interestingly, CD200 seemed to worsen survival in NPM 
mutated and in Flt3-ITD wild type patients, irrespectively 
of karyotype, so identifying a subset of patients with 
poor prognosis in a group usually associated with a more 
favorable outcome. A negative impact on OS was observed 
also in CD56 negative patients, that are usually considered 
to have a better prognosis compared to CD56+ patient. 
[36–38] Conversely, no differences in OS probability are 
evident evaluating CD200 and CD34 expression. It could be 
speculated that CD200 in CD34+ leukemic cell resembles 
the normal expression on CD34+ progenitors, where it 
contributes in protection from auto-aggression by the immune 
system cells. Despite the different rate of expression in de 
novo and secondary AML, CD200 expression had a negative 
impact on OS in both groups; 3-year survival in CD200+ de 
novo cases (36%) was similar to that of CD200- secondary 
AML (39%), and significantly lower than CD200- de novo 
(49%) but higher than CD200+ secondary (11%) patients, 
respectively. So, the combination of CD200 expression and 
leukemia type define three group of patients with significant 
different survival expectation (p = 0,0007).
Mechanisms by which CD200 exerts its negative 
influence on outcome are only partially defined. In the 
recent years the complex network connecting innate and 
adaptive immune cells to response to foreign pathogens, to 
self-antigens and to tumor cells begin to clarify, and their 
identification may contribute to the design of novel target 
therapies. Coles et al. observed a suppression of memory 
T-cells and a reduction of NK activity in CD200 positive 
AML patients, especially in the NK cells with high lytic 
activity [39, 40]. We did not find a significant reduction in 
NK populations in our population, but T-cells were studied 
on in a minority of cases, thus we cannot confirm the 
observation of an increased frequency of CD4+ regulatory 
cell and a recovery of Th1 response by Tregs depletion in 
CD200-positive leukemia [41]. In line with this findings, 
Memarian et al. reported high levels of IL10 production in 
autologous mixed lymphocyte reactions in presence of AML-
dendritic cells [42]. Coles and coworkers have hypothesized a 
co-operation between CD200/CD200R and PD-L1/PD-1 axis 
as a cause of the worse prognosis linked to overexpression of 
CD200 and PD-L1 on leukemic blast cells [43].
In our series, preliminary data indicate a higher 
occurrence of myeloid-derived suppressor cells (MDSC), 
that are known to play a central role in regulating immune 
response and tumor tolerance [21, 44–46], in CD200 
positive patients. Similar findings have been reported by 
Moertel et al. in human brain tumors [47]. They found that 
high levels of CD200 correlated with MDSC expansion 
and demonstrated, in an experimental model, that the 
block of CD200/CD200R prevents MDSC induction 
and inactivates the release of inhibitory cytokines. If 
confirmed, our data may be of interest not only for 
prognosis but also for the pathogenesis of AML. Chen et 
al have reported a role of MDSC in inducing multilineage 
cytopenia and cytological dysplasia [48].
In conclusion, our study confirms the negative 
prognostic role of CD200 in AML and identifies subgroups 
of patients in which CD200 significantly reduces survival 
probability. Of note, beside an additive negative impact in 
patients with unfavorable cytogenetic or secondary AML, 
CD200 overexpression is associated with a worse prognosis 
also in patients with biological markers considered favorable, 
such as mutated NPM, Flt3 wild type, negativity of CD34 and 
CD56 expression and, probably, CBF AML. Taken together, 
these findings can be useful in the management of AML 
patients. Novel therapeutic approaches could be designed 
in order to manipulate the immune microenvironment, 
reversing the “do not eat me signal” of CD200. Anti-CD200 
antibodies have demonstrated in vitro efficacy [49] and 
are under investigation in chronic lymphocytic leukemia 
[50]. Moreover many drugs able to deactivate MDSC [51, 
52], to block their development [53, 54] or to deplete them 
[54, 55] have been developed in the last years and will 
probably deeply change the therapeutic scenarios of 
hematologic malignancies.
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